Mercados españoles cerrados

Pfizer Inc. (PFE)

NYSE - NYSE Precio demorado. Divisa en USD
Añadir a la lista de favoritos
51,59+1,50 (+2,99%)
Al cierre: 04:05PM EDT
51,50 -0,09 (-0,17%)
Después del cierre: 07:59PM EDT
Inicia sesión para publicar un mensaje.
  • A
    Amy B.
    I can see either $MRNA or $PFE go for $TNXP preclinical monkey pox vaccine TNX-801 as it is THE ONLY monkey pox vaccine at preclinical level for partnership/buyout? The JYNNEOS Is not made in America - imports here does not solve the problem. Big bar@a will junk all over this
  • J
    JohnnyBGood
    $NVAX conversation
    $PFE and $MRNA trials had ZERO myocartis. NVAX has SIX (6)!!!! Did you people fail basic kindergarten math?????
  • J
    JohnD
    Cisco Systems, Inc.
    Growth is dead for all except $TSLA. The growth story is over. Here are the near term price targets: $CSCO $10, $INTC $5, $T $3, $QQQ $122.3756, $XOM $30, $PFE $5, $NVAX $1.30, $TSLA $4600.
  • P
    Pablo
    tranqui
  • K
    Keith
    $TLLTF conversation
    The Year is 2025………….

    $PFE bought into Jupiter late 2022 with 10% ownership taken for XX million

    The XX million was used for advancing #MedicalDeliveryDevice for medical Vaping ……..

    Massachusetts delivers every QTR for six straight quarters

    And $TLLTF position sold for $20 a share

    Just like $PLUG
  • H
    Hawdet
    WiMi Hologram Cloud Inc.
    Perfect entry point? Been watching $WIMI $F $PFE for a long time
  • J
    Johnson
    WiMi Hologram Cloud Inc.
    We have a long way to go, but we're seeing light at the end of the tunnel. $WIMI $PFE
  • M
    Michael1
    $NVAX conversation
    Single finger salute to $PFE frens
  • M
    MS
    Top 4 bullish trends $BB $PFE $ACB
    $NOK
  • H
    Hilary
    Venus Acquisition Corporation
    $VENA $AAL $PFE This is a very good lineup, if it can be maintained
  • B
    Blarney
    $TGTX conversation
    $PFE can just walk down the street and gobble up $TGTX at anytime now.

    Pfizer plans to spend capital on building its pipeline for second half of the decade, CEO Albert Bourla says.

    "You should expect to see a lot of Phase 2, Phase 3 business development deals that will allow us to bring in-house a lot of potential medicines," Bourla says.
  • S
    Simon
    $ATRS conversation
    Maybe Otrexup will get a boost for Rheumatoid Arthritis from Pfizers' failure in safety study for JAK Inhibitor Xeljenz--> see below:
    Pfizer's big blockbuster Xeljanz flunks its post-marketing safety study, renewing harsh questions for JAK class
    Jason Mast
    Editor

    When the FDA approved Pfizer’s JAK inhibitor Xeljanz for rheumatoid arthritis in 2012, they slapped on a black box warning for a laundry list of adverse events and required the New York drugmaker to run a long-term safety study.

    That study has since become a consistent headache for Pfizer and their blockbuster molecule. Last year, Pfizer dropped the entire high dose cohort after an independent monitoring board found more patients died in that group than in the low dose arm or a control arm of patients who received one of two TNF inhibitors, Enbrel or Humira.

    And on Wednesday, Pfizer announced that the six-year study had failed. Across 4,362 patients, those who received either a low or high dose of Xeljanz experienced more major cardiovascular events — such as stroke and heart attack — than those on Humira or Enbrel. They also had higher rates of cancer, with Pfizer failing to hit non-inferiority on both primary endpoints.

    Key questions, such as differences in mortality, have yet to be answered. Still, the study renews difficult questions for a class of drugs that has generated significant efficacy in autoimmune conditions but faced continual safety concerns. The FDA put black box warnings on both Xeljanz and Eli Lilly’s Olumiant and last year rejected Gilead’s filgotinib outright, ending the big biotech’s plan to develop the drug in the US.

    A Pfizer spokesperson noted in an email that, unlike in previous Xeljanz trials, participants in the latest study had to be over the age of 50 and have at least one cardiovascular risk factor. He said they were “continuing to evaluate the findings of this study” and will work with the FDA to review the full results.

    “At this point we cannot speculate on hypothetical market impact,” he said.

    An FDA spokesperson similarly demurred but said they would review adverse event reports and any other data sent to the agency.

    “We cannot speculate on whether labeling changes will be made for Pfizer’s Xeljanz,” he said.

    Investors, though, were quick to speculate about the impact for Pfizer $PFE, shaving 2.3% off its stock Thursday morning, or nearly $5 billion of market cap. Xeljanz has become essential to Pfizer’s portfolio as the New York pharma tries to double down on its pipeline, bringing $654 million in Q3 2020 alone.

    It’s also not yet clear how the new findings will impact JAK inhibitors more broadly. In a note to investors, RBC’s Brian Abrahams said physicians already take safety issues into account when considering JAK inhibitors, but that the new data could make the FDA “even more risk-averse on labeling for the class going forward.” That could impact Incyte as they await the FDA’s decision on a topical formulation for Jakafi, one of the only JAK inhibitors that does not yet have a black box warning.

    Meanwhile, Gilead’s decision to bail on filgotinib now appears prudent, he said, and newer, non-JAK approaches for autoimmune diseases could now gain steam.

    “Greater baggage on Xeljanz and JAK class could keep door open for other anti-inflammatory approaches in diseases like RA, psoriatic arthritis, and IBD, and benefit co’s pursuing such approaches,” Abrahams said, singling out Galapagos’ Toledo program of SIK inhibitors.

    The Pfizer study compared rheumatoid arthritis patients who received either 10mg Xeljanz, 5 mg Xeljanz or Humira, with just under 1,500 patients assigned to each group.

    In raw numbers, Xeljanz high and low dose patients had 51 and 47 cardiovascular events, compared with 37 for patients on Humira. When calculated as a percentage of person-years — a metric that simply adds up the total number of years each patient has been on the therapy — patients on Xeljanz saw 0.98 events per 100 years, compared with 0.73 events for Humira. That amounts to a 33% difference.

    For malignancies, Xeljanz patients saw 1.13 events per 100 years, compared to 0.77 events for cancer — a 47% difference.

    Although Pfizer had altered the study last year over concerns about mortality in the high dose, the company said there was no statistically significant difference between the two Xeljanz doses on either primary endpoint. Pfizer, though, said they are still collecting and analyzing data on differences in mortality and another major adverse event, pulmonary embolism.
  • K
    Kim
    $SRPT conversation
    from dough:
    DEBJIT - Nice explaination of why the BIG question is will $PFE present Western Blot microdystrophin data (and define if it is adjusted for fat and fibrotic tissue or not), dystrophin positive fibers, and vector genome copies per nucleus, similar to what $SRPT has provided
  • W
    Wisdom of Crowds
    $PFE yesterday a $cvs today - both strong beats. Love the low valuations and great strategic positions. Enjoy the return and yield but I am not planning to sell either as both companies undervalued in my opinion - analysts have been slow to upgrade as previous management teams underdelivered. Like to see share button backs from both to accelerate stock price upside!
  • S
    Shaw
    Advise - I bought $PFE during the hype season when $PFE was approved $41.80 yup I know that’s gotta hurt .. I was under the impression Stock will 🚀

    Should I add more $PFE in my portfolio to compensate the temp LOST or move on to other stocks?

    Thanks
  • M
    Metal Ox
    I am newly long $pfe. CNBC suggest lack of enthusiasm for Pfizer is because its pipeline, claim a patent cliff in 2025. What’s the patent status of Pfizer’s 3-5 highest sales drugs? Is the patent cliff red flag real. I recognize vaccine is a nice plus, but can vaccine offset losing patent for one or two top Pfizer drugs?
  • D
    Duke
    $PROG conversation
    The FDA approved Pfizer's $PFE Xeljanz for Treatment of Ankylosing Spondylitis and guess who has the patent for ingestion therapeutic technology which delivers Xeljanz to the large intestine? $PROG! Just another reason the short bashers are working overtime on here.😄
  • n
    nito
    $NVAX conversation
    Remarks by President Trump and Members of the Coronavirus Task Force in Meeting with Pharmaceutical Companies $PFE, $GILD, $MRNA, $REGN, $SNY, $GSK
    MR. ERCK: Mr. President, Mr. Vice President, thank you for saving the most exciting company for the last. (Laughter.) So we’re Novavax. We’re down the street in Maryland. We’re a vaccine company. We make the recombinant nanoparticles. We make respiratory vaccines. We have two in phase three trials. We have an RSV vaccine, where we vaccinated 4,600 pregnant women to protect infants from RSV disease and the youngest kids.

    We have a flu vaccine. We all know we need a better flu vaccine and we have one in phase three trials. We’re going to unblind in four weeks. It’s an exciting time for the company.

    But we actually — our company is focused on emerging infectious diseases. We’ve made two coronavirus vaccines. We made one for SARS. We made one for MERS. We tested MERS and — all the way through animal challenge trials and it showed 100 percent infection protection.

    We have an Ebola vaccine that what the NIH showed, in four different nonhuman primate studies, that we had 100 percent protection at extremely low doses.

    And we’ve made a pandemic flu vaccine for H7 and 9 and others. And we’ve twice now taken from the gene sequence to the first in human studies done in the 90 days and published it in the New England Journal. And we’re once again doing the same thing since the gene sequence was identified — I think it published on January 10th. We’ve taken the same recombinant nanoparticle platform and have been in animal studies for a couple of weeks. We expect data this week on — from one of them.

    THE PRESIDENT: On this? On corona?

    MR. ERCK: And on this — I’m sorry, on corona. Yes. And we’re going to the nonhuman primates this week with the coronavirus vaccine candidate.

    THE PRESIDENT: So what do you think in terms of timing? What do you do think?

    MR. ERCK: Timing is — what you hear around the table. As soon as we can get it to humans in the May-June timetable and in phase one study (inaudible) but we’ll have primate data.

    THE PRESIDENT: So those are unheard of speeds, I think. Right? Pretty much. We’ll make it very easy for you. Those are — and we have to be very safe. But those are unheard of speeds.

    Go ahead, please.

    MR. ERCK: No, and we’re trying to identify scale so that we can get to the billion (inaudible) scale both for — we have the vaccine antigen and adjuvant. And you put those together and you get the most promising result, we think. And so we desperately need and have good relationships with the FDA and to work with the FDA to see where, instead of waiting 30 days, for — to get to an IND, you get in 10 days or 21 — whatever the number is. But there are a lot of things that we can do with the FDA.

    And, frankly, we need money. We’re a biotech company, and not one of the larger pharma companies. And so we need money to get scale.

    THE PRESIDENT: But you work with the other companies also?

    MR. ERCK: And we have worked with the other companies and on this particular instance, we have not yet. But we can.
    https://www.whitehouse.gov/briefings-statements/remarks-president-trump-members-coronavirus-task-force-meeting-pharmaceutical-companies/
    Cabinet Room 3:20 P.M. EST THE PRESIDENT: Well, thank you very much. Today, we are meeting with the pharmaceutical and biotechnology companies — the biggest in the world, most prestigious, the ones that get down to the bottom line very quickly — to
    Cabinet Room 3:20 P.M. EST THE PRESIDENT: Well, thank you very much. Today, we are meeting with the pharmaceutical and biotechnology companies — the biggest in the world, most prestigious, the ones that get down to the bottom line very quickly — to
    www.whitehouse.gov
  • M
    Metal Ox
    Is biontech $bntx a partner in $pfe Pfizer’s planned new vaccine which can be stored at refrigerator temperature, or is Pfizer developing this follow up vaccine on its own?
  • e
    ed
    $PFE conversation
    Pfizer CEO
    @AlbertBourla
    on IP waivers:

    “truly believe that makes zero sense, not to mention about the disincentives that will create the whole biotech industry, if waiving the patents, What does it mean in the next pandemic?” $PFE